Nonclinical work in metabolic disease

Diabetes, dyslipidaemia and obesity are the conditions most development activity addresses in this area. They differ from many therapeutic areas in one respect that matters for nonclinical design: the animal models are numerous, well characterized and easy to establish, which makes the choice between them the substantive decision rather than the availability of any of them.

The population is large. The Centers for Disease Control and Prevention reports 38.4 million people with diabetes, 11.6 percent of the United States population,^[S1] and an obesity prevalence among adults aged 20 and over of 41.9 percent in the period from 2017 to March 2020.^[S2] Those figures matter to a nonclinical programme mainly through what they imply about the eventual safety requirements: a product intended for chronic use in a population of that size faces a different expectation for long-term safety data than one for a small population with a serious disease.

The models

Models divide into two groups, and they answer different questions. Genetic models carry a mutation that produces the phenotype: a review of experimental models for antidiabetic work names the obese mouse carrying the leptin mutation, the diabetic mouse carrying the leptin receptor mutation, and the Zucker diabetic fatty rat among them.^[S3] These develop the phenotype reliably and quickly, which is their value, and they do so through a single genetic lesion, which is their limit, since human metabolic disease is not monogenic.

Diet-induced models are the second group. Feeding a high-fat diet to a standard inbred strain produces obesity and insulin resistance over weeks to months, through a route closer to the human one. The trade-off is time and variability: the phenotype develops more slowly and less uniformly than in a genetic model, which affects group sizes and study duration.

Confounders that are documented rather than assumed

A review of mouse models in obesity research addresses their limitations directly and discusses confounding factors which, if taken into account, might improve the translatability of findings.^[S4] In practice the ones that most often affect a study are diet composition and the choice of control diet, housing temperature, since mice housed below thermoneutrality expend energy on heat production, sex, and the substrain used. None of these is exotic, and all of them should be stated in the protocol rather than left to the laboratory default, because a difference in any of them between a pilot study and the definitive one can account for a difference in result.

An example of current development activity

AstraZeneca announced an agreement with Eccogene covering ECC5004, which the company describes as a once daily, low dose, small molecule GLP-1 receptor agonist then in a United States phase 1 trial.^[S5] The first-in-human study is registered publicly.^[S6] The point of interest for a nonclinical audience is the modality: an orally administered small molecule addressing a target that approved products address with injected peptides. That changes the nonclinical package, since a small molecule brings metabolism, drug interaction and genotoxicity questions that a peptide does not.

The approved comparators

This class already has approved products. The Food and Drug Administration approved semaglutide injection for chronic weight management in adults with obesity or overweight, described in the announcement as the first such approval since 2014.^[S7] That is recorded here as a regulatory fact; this site does not discuss the efficacy of approved products or compare them. For a nonclinical programme the relevance is that an approved comparator exists, which shapes what a new candidate has to characterize and what questions a reviewer is likely to ask.

What to settle before placing the work

• {'items': ['Whether a genetic or a diet-induced model answers the question, since the first tests the compound against a single lesion and the second against a phenotype developed through a route closer to the human one.^[S3]', 'The exact diet, including the control diet, stated by product code rather than by fat percentage.', 'Housing temperature, sex and substrain, all of which the literature identifies as confounders in this area.^[S4]', 'How body composition is measured, since body weight alone does not distinguish loss of fat from loss of lean mass.', 'Whether the study is exploratory pharmacology, normally conducted outside the good laboratory practice regulation, or part of the regulated package.^[S8]']}

Summary

Models in this area are plentiful and easy to obtain, which makes the design decisions the substantive ones. Which model, on which diet, at which housing temperature, in which sex, measured how. The literature documents these as confounders rather than details,^[S4] and a protocol that leaves them to the laboratory default is leaving the most consequential choices unmade.

About this article

This is an independent editorial article for people who commission nonclinical work in the United States. It records approvals and development-stage announcements as facts, and does not discuss the efficacy of any product, approved or investigational, or compare treatments. It does not recommend any laboratory or model supplier. Last reviewed: September 3, 2026.

References

1. CDC — National Diabetes Statistics Report. https://www.cdc.gov/diabetes/php/data-research/index.html (accessed 2026-09-03)
2. CDC — Adult Obesity Facts. https://www.cdc.gov/obesity/php/data-research/adult-obesity-facts.html (accessed 2026-09-03)
3. Progress in experimental models to investigate the in vivo and in vitro antidiabetic activity of drugs. https://pubmed.ncbi.nlm.nih.gov/ (accessed 2026-09-03)
4. Navigating the Strengths and Constraints of Mouse Models in Obesity Research. https://pubmed.ncbi.nlm.nih.gov/ (accessed 2026-09-03)
5. AstraZeneca — AstraZeneca and Eccogene enter agreement for clinical-stage GLP-1RA, ECC5004(Official company announcement). https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-and-eccogene-enter-agreement-for-clinical-stage-glp-1ra.html (accessed 2026-09-03)
6. ClinicalTrials.gov — NCT05654831（FTIH of ECC5004 in Healthy and Diabetic Participants）. https://clinicaltrials.gov/study/NCT05654831 (accessed 2026-09-03)
7. FDA — FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014 (accessed 2026-09-03)
8. 21 CFR Part 58 — Good Laboratory Practice for Nonclinical Laboratory Studies (§58.1 scope). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-58 (accessed 2026-09-03)